Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
NIHR Bioresource Rare Diseases, |
RCV000851955 | SCV000899378 | likely pathogenic | von Willebrand disease type 1 | 2019-02-01 | criteria provided, single submitter | research | |
Laboratory of Hematology, |
RCV000851955 | SCV002546273 | pathogenic | von Willebrand disease type 1 | 2020-12-11 | criteria provided, single submitter | research | |
Laboratory of Hematology, |
RCV002245652 | SCV002546274 | pathogenic | von Willebrand disease type 2 | 2020-12-11 | criteria provided, single submitter | research | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV003478454 | SCV004221510 | likely pathogenic | not provided | 2022-05-14 | criteria provided, single submitter | clinical testing | The frequency of this variant in the general population, 0.000008 (1/125176 chromosomes, http://gnomad.broadinstitute.org), is consistent with pathogenicity. In the published literature, the variant has been reported in individuals and families affected with von Willebrand disease (PMID: 29893454 (2018)), Type 1 or 1H (PMID: 17190853 (2007), 28971901 (2017)), and Type 2A (PMID: 35452508 (2022)). It was also described in individuals having bleeding/platelet disorders (PMID: 31064749 (2019), 32640909 (2020)). Functional studies have also shown that this variant interferes with normal splicing and causes exon 26 skipping (p.Pro1127_Gly1180delinsArg) that results in defective multimerization, secretion, and FVIII binding activity (PMID: 23621778 (2013)). Based on the available information, this variant is classified as likely pathogenic. |
Center for Genomic Medicine, |
RCV003478454 | SCV004243462 | pathogenic | not provided | 2024-02-06 | criteria provided, single submitter | clinical testing | |
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, |
RCV002245652 | SCV002513364 | pathogenic | von Willebrand disease type 2 | 2022-04-26 | no assertion criteria provided | clinical testing |